CAMP4 Therapeutics
CAMP
CAMP4 Therapeutics (CAMP) news
Recent news
Camp4 Therapeutics Corp: Needham initiates coverage with buy rating; target price $8
AInvest Wire · 17h agoCamp4 Therapeutics Corp: Oppenheimer initiates coverage with outperform rating and price target $15
AInvest Wire · Oct 5, 2026Camp4 Therapeutics Corp - To initiate CMP-002 clinical trial in Q4 2026
Camp4 Therapeutics Corp has announced plans to initiate a clinical trial for its investigational compound CMP-002 in the fourth quarter of 2026[1]. The trial will follow the completion of preclinical studies and regulatory review, which are currently in progress. The company has not disclosed…
AInvest Wire · Sep 10, 2026Camp4 Therapeutics receives authorization in the United Kingdom for phase 1/2 human clinical trial of CMP-002 in patients with Syngap1-related disorder
AInvest Wire · Sep 10, 2026Camp4 Therapeutics closes $100M placement
AInvest Wire · Aug 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.